http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106967072-B

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
filingDate 2017-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2019-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2019-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-106967072-B
titleOfInvention Tofacitinib citrate crystal form compound and preparation method thereof
abstract The invention belongs to the technical field of medicines, and discloses a tofacitinib citrate crystal form compound and a preparation method thereof, wherein an X-ray powder diffraction pattern represented by a 2 theta +/-0.2-degree diffraction angle shows characteristic diffraction peaks at 2.42 degrees, 3.25 degrees, 4.23 degrees, 5.04 degrees, 6.12 degrees, 7.08 degrees, 8.02 degrees, 9.72 degrees, 10.63 degrees, 12.90 degrees, 14.35 degrees, 15.71 degrees, 17.82 degrees, 18.34 degrees, 19.24 degrees, 22.46 degrees, 24.56 degrees, 26.62 degrees, 30.75 degrees and 32.45 degrees, and an X-ray powder diffraction pattern obtained by using Cu-K alpha ray measurement is shown in figure 1 and is completely different from the prior art. The tofacitinib citrate crystal form compound has good water solubility and high stability, the preparation method is simple and easy to operate, the administration safety of the prepared pharmaceutical composition is greatly improved, and the tofacitinib citrate crystal form compound is very suitable for clinical application.
priorityDate 2017-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104292231-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104788461-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105348287-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2791141-B1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID301880
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10174505
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419476643
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411932836
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID702
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9926791
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419537701
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538410
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID180
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID301880
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID887
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID452847829

Total number of triples: 33.